Market Intelligence, Clinical Progress, and High-Purity Reagents for Metabolic Disease, Oncology, and Aging Research.
TarMart Solution Ecosystem & Related Targets
Comprehensive reagent toolkit for SIRT1 drug discovery. Select your modality below:
| Component / Network | Product Description | Product Link |
|---|---|---|
| Antigen | SIRT1 Full-Length & Catalytic Domain Recombinant Protein High purity (>95%), Endotoxin <1 EU/µg. Sequence Verified. Theoretical MW confirmed. |
View SIRT1 Products |
| Gene Delivery | SIRT1 Promise-ORF / Lentivirus Full-length ORF for stable cell line construction and cellular NAD+ pathway studies. |
View SIRT1 Products |
| Benchmark Ab | Anti-SIRT1 Monoclonal Antibody (Research Grade) Recombinant positive control for Western blot, Co-IP, and ChIP. |
View SIRT1 Products |
| Validator | SIRT1 siRNA Set For knockdown verification and cellular target engagement studies. |
View SIRT1 Products |
| Related Target A | SIRT2 Cytosolic paralog for selectivity counter-screening. |
View SIRT2 Products |
| Related Target B | SIRT3 Mitochondrial sirtuin homolog; essential for NAD+-dependent deacetylase selectivity counter-screening. |
View SIRT3 Products |
| Related Target C | SIRT6 Nuclear sirtuin involved in DNA repair and metabolism; synergistic anti-aging research. |
View SIRT6 Products |
| Related Target D | TP53 (p53) Canonical SIRT1 deacetylation substrate; functional readout partner for cellular assay validation. |
View TP53 Products |
| Related Target E | NAMPT NAD+ synthesis pathway enzyme; synergy with SIRT1 modulation. |
View NAMPT Products |
| Critical Assay Challenge | The TarMart Advantage (Technical Spec) |
|---|---|
| Allosteric activator & inhibitor site screening | Full-length and catalytic domain truncations available; catalytic-dead H363Y mutant included as negative control |
| Pan-sirtuin family selectivity & counter-screening | SIRT1–SIRT7 homolog panel proteins strictly verified by mass spec for off-target profiling |
| Cellular target engagement & knockdown | Validated siRNA and Promise-ORF lentivirus included for gain- and loss-of-function validation |
| Biophysical assay standards | High purity (>95%), endotoxin <1 EU/µg, theoretical MW confirmed by SDS-PAGE |
| Enzymatic Activity Preservation | Optimized expression systems ensuring active conformation and NAD+ binding domain integrity |
| Lack of Robust Controls | Sequence-verified benchmark antibodies and standard activators included for assay calibration |
Live SIRT1 R&D Tracker
Market data changes daily. Access the latest global pipeline status directly:
Global Clinical Landscape & Future Outlook
The race for SIRT1 therapeutics has evolved from early dietary supplement derivatives to highly specific small molecule allosteric modulators and inhibitors. The landscape is bifurcated between NAD+-competitive inhibitors for oncology and allosteric activators for metabolic and neurodegenerative indications. Following the setbacks of first-generation activators (SRT1720 class) due to pan-sirtuin off-target effects and bioavailability issues, the field is pivoting toward highly selective allosteric activators and CNS-penetrant inhibitors. The next wave of R&D emphasizes isoform-selective modulation, combination strategies with NAD+ precursors (NMN/NR), and emerging modalities such as PROTACs for targeted degradation in oncology.
Competitive Modality & Indication Snapshot
| Modality | Representative Players | Key Indications | Critical Assay Need (Why TarMart?) |
|---|---|---|---|
| Small Molecule Activators (STACs) | GSK, Sinclair Lab Spin-offs, Life Biosciences | Metabolic Disorders, NASH, Aging | Enzymatic Activity Assay (Need high-purity WT & allosteric mutant proteins) |
| Small Molecule Inhibitors | Oncology biotech, academia (e.g., Selisistat/EX-527) | Solid tumors, Huntington's disease, neurodegeneration | Selectivity assay (Need SIRT1 vs SIRT2/3 mutant & WT proteins) |
| NAD+ Boosters / Combinations | Nutraceutical & pharma crossover programs | Metabolic syndrome, longevity | Cellular overexpression & knockdown (Need Lentivirus & siRNA) |
| Gene Therapy / Delivery | Various academic / biotech | Neurodegeneration | Overexpression Validation (Need Lentivirus full-length ORF) |
| PROTACs / Degraders | Emerging biotechs | Specific oncology subtypes | Degradation Assays (Need precise antibodies for WB readout) |
Key Resistance and Mechanistic Insights
Resistance to SIRT1 modulators can arise from allosteric pocket mutations, NAD+ binding domain conformational changes, or competition from PARP1-mediated NAD+ depletion. The use of catalytic-dead H363Y mutant controls and NAD+ competition assays is critical to distinguish on-target effects from assay artifacts.